LAMININ RECEPTOR IN BREAST TISSUE, BENIGN AND MALIGNANT TUMORS

乳腺组织、良性和恶性肿瘤中的层粘连蛋白受体

• 批准号: 3939347
• 负责人: G J BRYANT
• 金额: --
• 依托单位: DIVISION OF CANCER BIOLOGY AND DIAGNOSIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3939347
• 关键词: basement membrane; bladder neoplasm; breast neoplasms; human tissue; metastasis; neoplasm /cancer invasiveness; pancreas neoplasms

Laminin, a major glycoprotein of basement membranes, exhibits saturable binding to the surface of certain neoplastic and normal cells. Examination of various cell types (i.e. human pancreatic carcinoma, melanoma and bladder carcinoma) via live cell binding techniques indicate the number of receptors to be 50- 110,000 per cell depending on cell type. In our laboratory, the laminin receptor has been isolated from human breast carcinoma cells and tissue and mouse melanoma cells. The receptor and subsequent ligand binding have been implicated to play an important role in tumor cell attachment, one of the steps in tumor invasion and metastasis. The proposed study is designed to measure and correlate laminin receptor binding capacity of breast tissues with clinical information. Laminin receptor binding capacity markedly differs between benign, malignant and normal human breast tissue. Preliminary studies indicate a 50- fold increase in specific laminin binding activity in malignant versus benign breast tissues. These findings suggest a site for possible intervention in the sequence of tumor invasion.

层粘连蛋白是基底膜的主要糖蛋白，表现出 可饱和结合到某些肿瘤和正常肿瘤的表面 细胞。 检查各种细胞类型（即人胰腺 癌、黑色素瘤和膀胱癌）通过活细胞 结合技术表明受体的数量为 50- 每个细胞 110,000 个，具体取决于细胞类型。 在我们的实验室里， 层粘连蛋白受体已从人乳腺癌中分离出来 细胞和组织以及小鼠黑色素瘤细胞。 受体和 随后的配体结合被认为发挥了 在肿瘤细胞附着中发挥重要作用，这是肿瘤细胞附着的步骤之一 肿瘤的侵袭和转移。 拟议的研究设计 测量和关联层粘连蛋白受体结合能力 具有临床信息的乳腺组织。 层粘连蛋白受体 良性、恶性和之间的结合能力明显不同 正常人体乳腺组织。 初步研究表明 50- 恶性细胞中特异性层粘连蛋白结合活性成倍增加 与良性乳腺组织相比。 这些发现建议建立一个网站 可能干预肿瘤侵袭的顺序。